The American Journal of Managed Care

FDA Approves First At-Home Subcutaneous Thyroid Eye Disease Treatment

The FDA approved satralizumab-mwge (Enspryng; Genentech) on October 15, 2026, for adults with thyroid eye disease (TED) ...
mindbodygreen

Want To Age Well? This Ancient Practice Has Some Science-Backed Benefits

That makes it a practical option for people who find traditional workouts difficult because of pain, limited mobility, or ...
Endocrinology Advisor

FDA Approves Enspryng as First Subcutaneous Therapy for TED

The FDA has approved Enspryng (satralizumab-mwge) for thyroid eye disease in adults, offering the first at-home subcutaneous IL-6 receptor antagonist for TED.
The Barre-Montpelier Times Argus

Together, We Transform 60+: Alpro Group Advance Early Thyroid Detection for Ageing Malaysians

Nationwide initiative brings thyroid awareness, health education, targeted TSH screening and referral closer to the community ...